VANCOUVER, B.C., Sept. 4, 2003 (PRIMEZONE) -- ProtoKinetix, Inc. (OTCBB:PKTX) formally announces the appointment of Dr. Maximilien Arella to its Scientific Advisory Board. Dr. Arella is a Professor at the Microbiology and Biotechnology Research Centre, INRS -- Institut, Armand -- Frappier, University du Quebec. He brings with him extensive international experience in the field of molecular biology and monoclonal antibody development. We look forward to working with Max and his research associates. Dr. Arella has already introduced the RECAF receptor site and the ProtoKinetix development program to several major European institutions with the objective of fast track collaboration.
The Private Securities Litigation Reform Act of 1995 provides a ``safe harbor'' for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission. Specifically, investors should be cautious as ProtoKinetix, Incorporated is presently a development stage biotechnology company with limited financial resources. This presents significant risk to investors. Existing and prospective investors should undertake a thorough due diligence process, as well as seek advice from a registered securities broker before considering an investment in this company.